BioAge Labs Inc.

Clinical-stage biopharma harnessing the biology of human aging to develop therapies for cardiometabolic disease. Following the late-2024 discontinuation of azelaprag (apelin agonist) after STRIDES Phase 2 safety findings, the pipeline is led by BGE-102, an oral brain-penetrant NLRP3 inhibitor in Phase 1 with best-in-class hsCRP reductions, advancing into a Phase 1b/2a proof-of-concept in diabetic macular edema mid-2026, alongside next-gen oral and parenteral APJ agonist programs targeting obesity.